Dmitry I. Trukhan , Anatoly F. Sulimov , Larisa Yu. Trukhan
Abstract
Dyslipidemia – increased blood levels of cholesterol, triglycerides and atherogenic lipoproteins and/or decreased levels of anti-atherogenic high-density lipoproteins. Dyslipidemia is considered one of the main biological risk factors for chronic non-communicable diseases, along with overweight and obesity, arterial hypertension and hyperglycemia. The initial stage of correction of dyslipidemia begins with dietary recommendations, in which omega-3 polyunsaturated fatty acids occupy an important place. The effects of the main substances included in the combined nutraceutical Cholesterol Control are considered: omega-3 polyunsaturated fatty acids, including eicosapentaenoic and docosahexaenoic acids, red yeast rice, coenzyme Q10, which allows us to consider it the nutraceutical of choice for low and moderate risk individuals with moderately elevated cholesterol and triglycerides, no indications for taking statins or the presence of contraindications to taking them. Periodontitis is the sixth most common disease in the world (second among dental pathologies after caries) and the leading cause of tooth loss in adults. At the beginning of the 21st century, the concept of “periodontal medicine” was formed, within the framework of which the bidirectional connection of periodontal pathology with systemic diseases of the body is considered. We searched the PubMed and Scopus information databases for articles published before 02/15/2024 that examined the relationship between dyslipidemia and periodontal pathology. The results obtained indicate the presence of a bidirectional relationship between dyslipidemia and periodontal pathology. The analysis showed the positive effect of omega-3 polyunsaturated fatty acids and coenzyme Q10 on the inflammatory process in periodontal tissue and allows us to consider the nutraceutical Cholesterol Control as an adjuvant therapy in comorbid patients with dyslipidemia and periodontal pathology, as well as for the prevention of lipid disorders in patients with periodontal diseases.
Keywords: dyslipidemia, cholesterol, triglycerides, omega-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, coenzyme Q10, red yeast rice, prevention, nutraceutical, periodontal pathology, periodontitis, comorbidity.
Keywords: dyslipidemia, cholesterol, triglycerides, omega-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, coenzyme Q10, red yeast rice, prevention, nutraceutical, periodontal pathology, periodontitis, comorbidity.
About the Author
Dmitry I. Trukhan 1 , Anatoly F. Sulimov 1 , Larisa Yu. Trukhan 11 Omsk State Medical University, Omsk, Russia
References
1. Трухан Д.И., Филимонов С.Н., Темникова Е.А. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. Гериатрические аспекты в кардиологии. СПб.: СпецЛит, 2022. Режим доступа: https://elibrary.ru/item.asp?id=48110916
Trukhan D.I., Filimonov S.N., Temnikova E.A. Diseases of the cardiovascular system: clinical picture, diagnosis and treatment. Geriatric aspects in cardiology. Saint Petersburg: SpetsLit, 2022. Available at: https: //elibrary.ru/item.asp?id=48110916 (in Russian).
2. Клинические рекомендации. Нарушения липидного обмена. Одобрено на заседании Научно-практического совета Министерства здравоохранения Российской Федерации (заседание от 27.12.2022). Режим доступа: https://cr.minzdrav.gov.ru/recomend/752_1
Clinical recommendations. Lipid metabolism disorders. Approved at a meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (meeting dated December 27, 2022). Available at: https://cr.minzdrav.gov.ru/recomend/752_1 (in Russian).
3. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. DOI: 10.15829/1728-8800-2022-3235
Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines 2022. Cardiovascular therapy and prevention. 2022;21(4):3235. DOI: 10.15829/1728-8800-2022-3235 (in Russian).
4. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular dis ease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38(32):2459-72. DOI: 10.1093/eurheartj/ehx144
5. Mozaffarian D, Lemaitre RN, King IB et al. Plasma Phospholipid Long-Chain – 3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults. Ann Intern Med 2013;158(7):515-25. DOI: 10.7326/0003-4819-158-7-201304020-00003
6. Yang Q, Zhang Z, Gregg EW et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014;174(4):516-24. DOI: 10.1001/jamainternmed.2013.13563
7. Abdelhamid AS, Brown TJ, Brainard JS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020;3(3):CD003177. DOI: 10.1002/ 14651858.CD003177.pub5
8. Watanabe Y, Tatsuno I. Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. Expert Rev Clin Pharmacol 2021;14(1):79-93. DOI: 10.1080/17512433.2021. 1863784
9. Rodriguez D, Lavie CJ, Elagizi A, Milani RV. Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health. Nutrients 2022;14(23):5146. DOI: 10.3390/nu14235146
10. Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol 2020;40(5):1135-47. DOI: 10.1161/ATVBAHA.119.313286
11. Djuricic I, Calder PC. Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health. Annu Rev Pharmacol Toxicol 2023;63:383-406. DOI: 10.1146/annurev-pharmtox-051921-090208
12. Trivedi K, Le V, Nelson JR. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgrad Med 2021;133(1):28-41. DOI: 10.1080/00325481.2020.1783937
13. Bhatt DL, Steg PG, Miller M et al; REDUCE-IT Investigators Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792
14. Cicero AFG, Fogacci F, Banach M. Red Yeast Rice for Hypercholesterolemia. Methodist Debakey Cardiovasc J 2019;15(3):192-9. DOI: 10.14797/mdcj-15-3-192
15. Cicero AFG, Fogacci F, Stoian AP, Toth PP. Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review. Nutrients 2023;15(10):2288. DOI: 10.3390/nu15102288
16. Lu Z, Kou W, Du B et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol 2008;101(12):1689-93. DOI: 10.1016/j.amjcard.2008.02.056
17. Mazza A, Schiavon L, Rigatelli G et al. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food Funct 2018;9(7):3845-52. DOI: 10.1039/c8fo00415c
18. Cicero AFG, Fogacci F, Zambon A. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. J Am Coll Cardiol 2021;77(5):620-8. DOI: 10.1016/j.jacc.2020.11.056
19. Fogacci F, Giovannini M, Di Micoli V et al. Evaluation of the effect of a dietary supplementation with a red yeast rice and fish oil-containing nutraceutical on lipid pattern, high sensitivity C-reactive protein, and endothelial function in moderately hypercholesterolaemic subjects: a double-blind, placebo-controlled, randomized clinical trial. Arch Med Sci Atheroscler Dis 2023;8:e182-e189. DOI: 10.5114/amsad
/177444
20. Mantle D, Turton N, Hargreaves IP. Depletion and Supplementation of Coenzyme Q10 in Secondary Deficiency Disorders. Front Biosci (Landmark Ed) 2022;27(12):322. DOI: 10.31083/j.fbl2712322
21. Hargreaves I, Heaton RA, Mantle D. Disorders of Human Coenzyme Q10 Metabolism: An Overview. Int J Mol Sci 2020;21(18):6695. DOI: 10.3390/ijms21186695
22. Аронов Д.М. Применение коэнзима Q10 в кардиологической практике. РМЖ. 2004;15:905. Режим доступа: https://www.rmj.ru/articles/kardiologiya/Primenenie_koenzima_Q10_v_kardiologicheskoy_praktike/#ixzz8UcUZtEBA
Aronov D.M. Application of coenzyme Q10 in cardiological practice. RMJ. 2004;15:905. Available at: https://www.rmj.ru/articles/kardiologiya/Primenenie_koenzima_Q10_v_kardiologicheskoy_praktike/#ixzz8UcUZtEBA (in Russian).
23. Медведев О.С., Каленикова Е.И., Городецкая Е.А., Шашурин Д.А. Коэнзим Q10 в кардиологической практике – теоретические основы и результаты клинических исследований. РМЖ. 2009; 18: 1177. Режим доступа: https://www.rmj.ru/articles/kardiologiya/Koenzim_Q10_v_kardiologicheskoy_praktike__teoreticheskie_osnovy_i_rezulytaty__klinicheskih_issledovaniy/#ixzz8UcZmFdtQ
Medvedev O.S., Kalenikova E.I., Gorodetskaya E.A., Shashurin D.A. Coenzyme Q10 in cardiological practice – theoretical foundations and results of clinical studies. RMJ. 2009; 18: 1177. Available at: https://www.rmj.ru/articles/kardiologiya/Koenzim_Q10_v_kardiologicheskoy_praktike__teoreticheskie_osnovy_i_rezulytaty__klinicheskih_issledovaniy/#ixzz8UcZmFdtQ (in Russian).
24. Дзугкоев С.Г., Гармаш О.Ю., Дзугкоева Ф.С. Патогенетическое обоснование применения ингибитора 3-гидрокси-3-метилглутарил-коэнзим А редуктазы и антиоксиданта коэнзима Q10 в лечении и профилактике сердечно-сосудистой патологии. Кардиоваскулярная терапия и профилактика. 2021;20(6):2793. DOI: 10.15829/ 1728-8800-2021-2793
Dzugkoev S.G., Garmash O.Yu., Dzugkoeva F.S. Pathogenetic rationale for using an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase and an antioxidant coenzyme Q10 in the treatment and prevention of cardiovascular disease. Cardiovascular Therapy and Prevention. 2021;20(6):2793. DOI: 10.15829/1728-8800-2021-2793 (in Russian).
25. Мареев В.Ю., Мареев Ю.В., Беграмбекова Ю.Л. Коэнзим Q10 в лечении больных с хронической сердечной недостаточностью и сниженной фракцией выброса левого желудочка: систематический обзор и мета-анализ. Кардиология. 2022;62(6):3-14. DOI: 10.18087/cardio.2022.6.n2050
Mareev V.Yu., Mareev Yu.V., Begrambekova Yu.L. Coenzyme Q10 in the treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: a systematic review and meta-analysis. Cardiology. 2022;62(6):3-14. DOI: 10.18087/cardio.2022.6.n2050 (in Russian).
26. Mortensen AL, Rosenfeldt F, Filipiak KJ. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the
Q-SYMBIO randomized double-blind trial. Cardiology Journal 2019;(26):147-6.
27. Клинические рекомендации (протоколы лечения) при диагнозе пародонтит. Режим доступа: http://www.e-stomatology.ru/director/protokols_30-09-2014/
Clinical guidelines (treatment protocols) in the diagnosis of periodontitis. Available at: http://www.e-stomatology.ru/director/protokols_30-09-2014 (in Russian).
28. Всемирная организация здравоохранения. Информационные бюллетени. Охрана здоровья полости рта. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/oral-health
World Health Organization. Oral health. Available at: https://www. who.int/ru/news-room/fact-sheets/detail/oral-health (in Russian).
29. Трухан Д.И., Трухан Л.Ю. Взаимоотношения болезней пародонта и сердечно-сосудистых заболеваний. Международный журнал сердца и сосудистых заболеваний. 2016;(11):15-24. DOI: 10.24412/2311-1623-2016-11-15-24
Trukhan D.I., Trukhan L.Yu. Relationship between periodontal and cardiovascular diseases. International Heart and Vascular Disease Journal. 2016;(11):15-24. DOI: 10.24412/2311-1623-2016-11-15-24 (in Russian).
30. Van Dyke TE, Starr JR. Unraveling the link between periodontitis and cardiovascular disease. J Am Heart Assoc 2013;2(6):e000657. DOI: 10.1161/JAHA.113.000657
31. O'Dwyer MC, Furgal A, Furst W et al. The Prevalence of Periodontitis Among US Adults with Multimorbidity Using NHANES Data 2011-2014. J Am Board Fam Med 2023;36(2):313-24. DOI: 10.3122/jabfm.2022.220207R1
32. Pietropaoli D, Cairo F, Citterio F et al. Italian working group on Hypertension and Periodontitis (Hy-Per Group). Practical Guidelines for Patients with Hypertension and Periodontitis. High Blood Press Cardiovasc Prev 2023;30(1):7-16. DOI: 10.1007/s40292-022-00553-2
33. Del Pinto R, Landi L, Grassi G et al; Italian working group on Hypertension, Periodontitis (Hy-Per Group). Hypertension and periodontitis: A joint report by the Italian society of hypertension (SIIA) and the Italian society of periodontology and implantology (SIdP). Oral Dis 2023;29(2):803-14. DOI: 10.1111/odi.14009
34. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Коморбидность ревматоидного артрита и заболеваний пародонта. Медицинский совет. 2024;18(5):60-9. DOI: 10.21518/ms2024-079
Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Comorbidity of rheumatoid arthritis and periodontal diseases. Meditsinskiy Sovet. 2024;18(5):60-9. DOI: 10.21518/ms2024-079 (in Russian).
35. Трухан Д.И., Трухан Л.Ю. Пародонтит и сердечно-сосудистые заболевания: параллельно или в одной связке? Consilium Medicum. 2015;17(5):73-9. Режим доступа: https://elibrary.ru/item.asp? id=23762074
Trukhan D.I., Trukhan L.Yu. Periodontal and cardiovascular diseases: In parallel or in a bundle? Consilium Medicum. 2015;17(5):73-9. Available at: https://elibrary.ru/item.asp?id=23762074 (in Russian).
36. Трухан Д.И., Трухан Л.Ю. Некоторые аспекты коморбидности пародонтита и сердечно-сосудистых заболеваний. Медицинский совет. 2015;(17):12-6. Режим доступа: https://elibrary.ru/item.asp?id= 25450351
Trukhan D.I., Trukhan L.Yu. Some aspects of comorbidity of periodontitis and cardiovascular diseases. Medical advice. 2015;(17):12-6. Available at: http://elibrary.ru/item.asp?id=25450351 (in Russian).
37. Трухан Д.И., Трухан Л.Ю., Иванова Д.С. Коморбидность заболеваний сердечно-сосудистой системы и болезней органов пищеварения с изменениями органов и тканей полости рта. Клинический разбор в общей медицине. 2021;(3):6-17. DOI: 10.47407/kr2021.2.3. 00044
Trukhan D.I., Trukhan L.Yu, Ivanova D.S. Comorbidity of diseases of the cardiovascular system and diseases of the digestive organs with changes in organs and tissue of the oral cavity. Clinical review for general practice. 2021;(3):6-17. DOI: 10.47407/kr2021.2.3.00044 (in Russian).
38. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Возможные ассоциации патологии пародонта и новой коронавирусной инфекции (COVID-19). Клинический разбор в общей медицине. 2022;(2):6-12. DOI: 10.47407/kr2022.3.2.00120
Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Possible associations of periodontal pathology and new coronavirus infection (COVID-19). Clinical review for general practice. 2022;(2):6-12. DOI: 10.47407/kr2022. 3.2.00120 (in Russian).
39. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Коморбидность артериальной гипертензии и пародонтита: стоматологическая гипертензия. Клинический разбор в общей медицине. 2023;4(6):62-8. DOI: 10.47407/kr2023.4.5.00273
Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Comorbidity of arterial hypertension and periodontitis: dental hypertension. Clinical review for general practice. 2023;4(6):62-8. DOI: 10.47407/kr2023.4.5.00273 (in Russian).
40. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Ассоциация артериальной гипертензии и патологии пародонта: обзор новых данных. Фарматека. 2023;30(9-10):40-51. DOI: 10.18565/pharmateca.2023.9-10.40-51
Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Association of arterial hypertension and periodontal disease: a review of new data. Farmateka. 2023;30(9-10):40-51. DOI: 10.18565/pharmateca.2023.9-10.40-51 (in Russian).
41. Zhang DH, Yuan QN, Zabala PM et al. Diabetic and cardiovascular risk in patients diagnosed with periodontitis. Aust Dent J 2015;60(4):455-62. DOI: 10.1111/adj.12253
42. Salvi GE, Carollo-Bittel E, Lang NP. Effects the diabetes mellitus on periodontal and peri-implant conditions: update on associations and risks. J Clin Periodontol 2008;35(8 Suppl):398-409. DOI: 10.1111/j.1600-051X.2008.01282.x
43. Vieira CL, Cury PR, Miname MH et al. Severe periodontitis is associated with diastolic blood pressure elevation in individuals with heterozygous familial hypercholesterolemia: a pilot study. J Periodontol 2011;82(5):683-8. DOI: 10.1902/jop.2010.100496
44. Golpasand Hagh L, Zakavi F, Hajizadeh F, Saleki M. The association between hyperlipidemia and periodontal infection. Iran Red Crescent Med J 2014;16(12):e6577. DOI: 10.5812/ircmj.6577
45. Sandi RM, Pol KG, Basavaraj P et al. Association of Serum Cholesterol, Triglyceride, High and Low Density Lipoprotein (HDL and LDL) Levels in Chronic Periodontitis Subjects with Risk for Cardiovascular Disease (CVD): A Cross Sectional Study. J Clin Diagn Res 2014;8(1):214-6. DOI: 10.7860/JCDR/2014/6686.3927.
46. Vieira RW. Cardiovascular and periodontal diseases. Rev Bras Cir Cardiovasc 2014;29(1):VII-IX. DOI: 10.5935/1678-9741.20140003
47. Zeigler CC, Wondimu B, Marcus C, Modéer T. Pathological periodontal pockets are associated with raised diastolic blood pressure in obese adolescents. BMC Oral Health 2015;15(1):41. DOI: 10.1186/s12903-015-0026-6
48. Lianhui Y, Meifei L, Zhongyue H, Yunzhi F. Association between chronic periodontitis and hyperlipidemia: a Meta-analysis based on observational studies. Hua Xi Kou Qiang Yi Xue Za Zhi 2017;35(4):419-26. DOI: 10.7518/hxkq.2017.04.015
49. Xu J, Duan X. Association between periodontitis and hyperlipidaemia: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2020;47(11):1861-73. DOI: 10.1111/1440-1681.13372
50. Leite AC, Carneiro VM, Guimarães Mdo C. Effects of periodontal therapy on C-reactive protein and HDL in serum of subjects with periodontitis. Rev Bras Cir Cardiovasc 2014;29(1):69-77. DOI: 10.5935/1678-9741.20140013
51. Caúla AL, Lira-Junior R, Tinoco EM, Fischer RG. The effect of periodontal therapy on cardiovascular risk markers: a 6-month randomized clinical trial. J Clin Periodontol 2014;41(9):875-82. DOI: 10.1111/jcpe.12290
52. Friedewald VE, Kornman KS, Beck JD et al. The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. J Periodontol 2009;(80):1021-32. DOI: 10.1902/jop.2009.097001
53. Salminen A, Määttä AM, Mäntylä P et al. Systemic Metabolic Signatures of Oral Diseases. J Dent Res 2024;103(1):13-21. DOI: 10.1177/00220345231203562
54. Ramirez-Tortosa MC, Quiles JL et al. Periodontitis is associated with altered plasma fatty acids and cardiovascular risk markers. Nutr Metab Cardiovasc Dis 2010;20(2):133-9. DOI: 10.1016/j.numecd.2009. 03.003
55. Sculley DV. Periodontal disease: modulation of the inflammatory cascade by dietary n-3 polyunsaturated fatty acids. J Periodontal Res 2014;49(3):277-81. DOI: 10.1111/jre.12116
56. Panezai J, van Dyke T. Polyunsaturated Fatty Acids and Their Immunomodulatory Actions in Periodontal Disease. Nutrients 2023;15(4):821. DOI: 10.3390/nu15040821
57. Naqvi AZ, Hasturk H, Mu L et al. Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial. J Dent Res 2014;93(8):767-73. DOI: 10.1177/0022034514541125
58. Tabbaa M, Golubic M, Roizen MF, Bernstein AM. Docosahexaenoic acid, inflammation, and bacterial dysbiosis in relation to periodontal disease, inflammatory bowel disease, and the metabolic syndrome. Nutrients 2013;5(8):3299-310. DOI: 10.3390/nu5083299
59. Azzi DV, Viafara JAS, Zangeronimo MG et al. n-3 Ingestion may modulate the severity of periodontal disease? Systematic review. Crit Rev Food Sci Nutr 2018;58(11):1937-42. DOI: 10.1080/10408398. 2017.1278677
60. Sun M, Zhou Z, Dong J et al. Antibacterial and antibiofilm activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against periodontopathic bacteria. Microb Pathog 2016;99:196-203. DOI: 10.1016/j.micpath.2016.08.025
61. Sun M, Dong J, Xia Y, Shu R. Antibacterial activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against planktonic and biofilm growing Streptococcus mutans. Microb Pathog 2017;107:212-8. DOI: 10.1016/j.micpath.2017.03.040
62. Sette-de-Souza PH, Silva Bezerra WMD, Gomes Dantas MK et al. Identification of docosahexaenoic and eicosapentaenoic acids multiple targets facing periodontopathogens. Microb Pathog 2021;161(Pt A):105266. DOI: 10.1016/j.micpath.2021.105266
63. El-Sharkawy H, Aboelsaad N, Eliwa M et al. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J Periodontol 2010;81(11):1635-43. DOI: 10.1902/jop.2010.090628
64. Maybodi FR, Fakhari M, Tavakoli F. Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial. BMC Oral Health 2022;22(1):521. DOI: 10.1186/s12903-022-02569-5
65. Stańdo M, Piatek P, Namiecinska M et al. Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial. Nutrients 2020;12(9):2614. DOI: 10.3390/nu12092614
66. Kujur SK, Goswami V, Nikunj AM et al. Efficacy of omega 3 fatty acid as an adjunct in the management of chronic periodontitis: A randomized controlled trial. Indian J Dent Res 2020;31(2):229-35. DOI: 10.4103/ijdr.IJDR_647_18
67. Kruse AB, Kowalski CD, Leuthold S et al. What is the impact of the adjunctive use of omega-3 fatty acids in the treatment of periodontitis? A systematic review and meta-analysis. Lipids Health Dis 2020;19(1):100. DOI: 10.1186/s12944-020-01267-x
68. Wadia R. Periodontitis and omega-3 fatty acids. Br Dent J 2022;232(8):533. DOI: 10.1038/s41415-022-4212-z
69. Wadia R. Omega 3 fatty acids for periodontitis patients. Br Dent J 2022;233(2):122. DOI: 10.1038/s41415-022-4516-z
70. Van Ravensteijn MM, Timmerman MF, Brouwer EAG, Slot DE. The effect of omega-3 fatty acids on active periodontal therapy: A systematic review and meta-analysis. J Clin Periodontol 2022;49(10):1024-37. DOI: 10.1111/jcpe.13680
71. Heo H, Bae JH, Amano A et al. Supplemental or dietary intake of omega-3 fatty acids for the treatment of periodontitis: A meta-analysis. J Clin Periodontol 2022;49(4):362-77. DOI: 10.1111/jcpe.13603
72. Miroult C, Lasserre J, Toma S. Effects of Omega-3 as an adjuvant in the treatment of periodontal disease: A systematic review and meta-analysis. Clin Exp Dent Res 2023;9(4):545-56. DOI: 10.1002/cre2.736
73. Castro Dos Santos NC, Furukawa MV, Oliveira-Cardoso I et al. Does the use of omega-3 fatty acids as an adjunct to non-surgical periodontal therapy provide additional benefits in the treatment of periodontitis? A systematic review and meta-analysis. J Periodontal Res 2022;57(3):435-47. DOI: 10.1111/jre.12984
74. Chatterjee D, Chatterjee A, Kalra D et al. Role of adjunct use of omega 3 fatty acids in periodontal therapy of periodontitis. A systematic review and meta-analysis. J Oral Biol Craniofac Res 2022;12(1):55-62. DOI: 10.1016/j.jobcr.2021.10.005
75. Woelber JP, Reichenbächer K, Groß T et al. Dietary and Nutraceutical Interventions as an Adjunct to Non-Surgical Periodontal Therapy-A Systematic Review. Nutrients 2023;15(6):1538. DOI: 10.3390/ nu15061538
76. Prakash S, Sunitha J, Hans M. Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol 2010;42(6):334-7. DOI: 10.4103/0253-7613.71884
77. Mantle D, Turton N, Hargreaves IP. Depletion and Supplementation of Coenzyme Q10 in Secondary Deficiency Disorders. Front Biosci (Landmark Ed) 2022;27(12):322. DOI: 10.31083/j.fbl2712322
78. Merle CL, Lenzen C, Schmalz G, Ziebolz D. Systematic Review on Protocols of Coenzyme Q10 Supplementation in Non-Surgical Periodontitis Therapy. Nutrients 2023;15(7):1585. DOI: 10.3390/nu15071585
79. Rasoolzadeh EA, Shidfar F, Rasoolzadeh RA, Hezaveh ZS. The effect of coenzyme Q10 on periodontitis: a systematic review and meta-analysis of clinical trials. J Evid Based Dent Pract 2022;22(2):101710. DOI: 10.1016/j.jebdp.2022.101710
For citation:Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Comorbidity of dyslipidemia and periodontal diseases. Clinical analysis in general medicine. 2024; 5 (2): 21–30 (In Russ.). DOI: 10.47407/kr2023.5.2.00384
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
